Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


LSP BioVentures leads $10 million Series C investment in BioProcessors


Amsterdam, August 8th, 2007

LSP BioVentues announces today that it has lead the closing of a $10 million Series C equity investment round in BioProcessors Corporation, the leading provider of micro-engineered solutions for biopharmaceutical process development applications for the biotechnology and pharmaceutical industries. LSP joined existing investors Oxford Bioscience Partners, HLM Venture Partners, Healthcare Ventures, and New Science Ventures who also participated in this financing round.

BioProcessors’ SimCell™ platform is the first fully-integrated cell culture experiment management system for bioprocess development capable of generating data scalable to large-scale bioreactors. SimCell’s solutions allow customers to increase their cell culture experimental capacity by at least a factor of 100 over traditional bench-top equipment, enabling thousands of experiments to be completed in parallel. In addition to increased efficiency, SimCell also provides better data quality, reduces risk and lowers operating costs associated with conventional processing methods. This market leading system is coupled with proprietary software that allows for the robust storage and analysis of the large experimental data sets generated by the platform. BioProcessors’ clients include leading biotechnology and pharmaceutical companies such as Amgen, Novo Nordisk and Invitrogen.

'We are looking forward to LSP joining the BioProcessors investment partners, and with this round of financing being able to execute on our global sales and marketing plan,' said Jon Rennert, CEO of BioProcessors. 'We value their belief in our company and our ability to provide a solution for a long standing problem in the biotechnology industry.'

Dr. Fouad Azzam, General Partner at LSP BioVentures, commented: 'We are very excited about joining the existing investor base at BioProcessors. The company has proven that they have a solution for a long standing problem in the iotechnology industry, and provide significant value for their customers.'

About BioProcessors

Based in Woburn, MA, BioProcessors Corporation was founded in October, 2000 by Andrey J. Zarur, Ph.D. BioProcessors’ SimCell solutions provide biotechnology and pharmaceutical companies with a proven platform to exponentially increase experimental throughput and to enable scalability to production bioreactors at optimized yields.
For more information, please visit www.bioprocessors.com.

About LSP BioVentures

LSP BioVentures is a US based life science fund which was launched in June 2006. The fund invests primarily in early to mid-stage product and platform companies covering a variety of sectors including: agriculture, food & nutrition, health & wellness, Cleantech and platform technologies. LSP BioVentures is the fourth fund under the LSP Group.

LSP Group provides private equity financing to early- to mid-stage life-science companies in Europe and the US. With over $500 million under management and offices in Amsterdam, Munich and Boston, LSP Boston, LSP has over two decades of experience as specialist life-science investors. For more information about the LSP Group, please visit our website at www.lspvc.com.

For further information please contact:

LSP BioVentures
Boston, USA
Tel : (617) 452 1000


Publisher Contact Information:

LSP BioVentures
+1 (617) 452 1000
-

Company profile of Life Sciences Partners (LSP)
Past press releases of Life Sciences Partners (LSP).

Data


26,230
Tech investments
From our Online Data Service
16,944
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.